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doi:10.1016/j.jtcvs.2006.02.063bjective: At present, even when early-stage, small-sized non–small cell lung cancers
re being increasingly detected, lesser resection has not become the treatment of
hoice. We sought to compare sublobar resection (segmentectomy or wedge resec-
ion) with lobar resection to test which one is the appropriate procedure for such
esions.
ethods: From 1992 to 2001, a nonrandomized study was performed in 3 institutes
or patients with a peripheral cT1N0M0 non–small cell lung cancer of 2 cm or less
ho were able to tolerate a lobectomy. The results of the sublobar resection group
nrolled preoperatively (n  305) were compared with those of the lobar resection
roup (n  262).
esults: Except for distribution of tumor location, there were no significant differ-
nces in any variable, patient characteristics, curability, pathologic stage, morbidity,
r recurrence rate. Median follow-up was more than 5 years. Disease-free and
verall survivals were similar in both groups with 5-year survivals of 85.9% and
9.6% for the sublobar resection group and 83.4% and 89.1% for the lobar resection
roup, respectively. Multivariate analysis confirmed that the recurrence rate and
rognosis associated with sublobar resection were not inferior to those obtained with
obar resection. Postoperative lung function was significantly better in patients who
nderwent sublobar resection.
onclusions: Sublobar resection should be considered as an alternative for stage IA
on–small cell lung cancers 2 cm or less, even in low-risk patients. These results
ould lay the foundation for starting randomized controlled trials anew, which
ould bring great changes of lung cancer surgery in this era of early detection of
ung cancer.
n the one and only randomized study to compare lobectomy and sublobar
resection for stage IA non–small cell lung cancer (NSCLC) published in 1995,
the Lung Cancer Study Group (LCSG) demonstrated a 3-fold increase in the
ocal recurrence rate among patients who underwent sublobar resection,1 and
owerfully supported the indisputable dogma that lobectomy is the standard of care
or stage I NSCLC. However, the most broadly referenced report included poten-
ially misleading statements and analyses insufficient to advocate the superiority of
obectomy over sublobar resection as some investigators then and later
emonstrated.2-4
With the dramatic upsurge in early detection of ever smaller NSCLCs through
he development of radiographic tools such as high-resolution computed tomogra-
hy (CT) and the widespread practice of low-dose helical CT for screening,5 which
s rapidly changing clinical practice, many surgeons have inevitably become con-
erned over the unified treatment of these small peripheral lesions with whole
obectomy. Generally, patients with a larger tumor have a poorer prognosis and a
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TSigher frequency of hematogenous and lymphatic metasta-
es, whereas smaller tumors such as bronchioloalveolar
arcinoma usually have a more indolent biologic behavior.
s it uniformly required to extirpate the entire lobe for such
iny peripheral lesions when sufficient margins of resection
an be achieved with sublobar resection? Removing a rel-
tively large volume of healthy lung tissue may result in a
igher frequency of operative morbidity and poorer quality
f postoperative life, reducing the chance for further resec-
ions because these patients survive long enough to be at
isk for a second or even a third NSCLC. The incidence of
econd primary lung cancers may be approximately 3% per
ear6,7; thus patients who survive 5 or more years after their
rst resection would face a significant cumulative danger of
econd cancers. The larger the amount of the initial resec-
ion, the more restricted the surgical options for next
esections.
Recently, several reports demonstrated that sublobar re-
ection was not inferior to lobectomy regarding the prog-
osis of patients with small-sized NSCLC,8-13 but the num-
er of cases evaluated in those studies was relatively small.
he present study, in which we compared the outcome of
ublobar resection with that of lobectomy in low-risk non-
ompromised patients with a T1N0 NSCLC 2 cm or less in
ize, is the largest series published so far on radical sublobar
esection and followed for long-term outcome. The rigid
onsensus on lobectomy for stage I cancers has never per-
itted us to carry out a randomized study. In such a situa-
ion in which it has been difficult even to plan a randomized
rial because of ethical reasons, a well-designed observa-
ional trial may function as an effective reference for a
uture randomized trial. This was a nonrandomized study
n which the decision on whether to be assigned to the
ublobar resection group or the lobar resection group was
aken by the patients themselves. Because the 2 groups
ere well matched for known prognostic variables, a com-
arison between the 2 groups was considered scientifically
alid.
ethods
atients
n 3 institutes during a 10-year period, from January 1992 to
ecember 2001, patients were enrolled for entry into this study
hen they had a clinical T1N0M0 peripheral tumor of 2 cm or less
Abbreviations and Acronyms
CT  computed tomography
FEV1  forced expiratory volume in 1 second
FVC  forced vital capacity
LCSG  Lung Cancer Study Group
NSCLC non–small cell lung cancern every dimension located in the outer one third of the lung on CT e
70 The Journal of Thoracic and Cardiovascular Surgery ● Octoonfirmed to be an NSCLC. Patients included in the study were
ble to tolerate a lobectomy as evaluated by cardiopulmonary
unctional tests, had no history of previously treated cancer, and
rovided his/her informed written consent based on the approved
rotocol of each institute’s review board before registration and
urgery. Patients with a tumor located in the right middle lobe were
xcluded. Radionuclide bone scan and CT examination of the
rain, chest, and upper abdomen were routinely required to detect
ossible metastases. At the time of registration, every patient was
ssigned to undergo lobectomy or sublobar resection in compli-
nce with his/her decision. In other words, patients were allocated
o the sublobar resection group if the patient consented to the
ublobar resection, and to the lobectomy group if the patient did
ot consent to sublobar resection. Patients were invariably sched-
led to undergo lobectomy or sublobar resection before the thora-
otomy. During the operation, the tumor status was confirmed by
he surgeon to be T1N0 on the basis of frozen-section analysis of
ampled segmental, lobar, hilar, and mediastinal lymph nodes from
he drainage area of the tumor and pleural lavage cytology. In
atients assigned to the sublobar resection group, the surgeon
autiously evaluated the appropriateness of a sublobar resection
or curative treatment and whether the deliberate procedure would
e a segmentectomy or an adequate large wedge resection. Basi-
ally, the wedge resection could be used as a sublobar resection for
tumor of 1.5 cm or smaller in diameter and a tumor observed as
ure ground-glass opacity by CT, when considered appropriate.
esected specimens were examined histopathologically, and his-
ologic typing was done according to the World Health Organiza-
ion classification.14 Surgical–pathologic staging was performed
ccording to the New International Staging System for Lung
ancer.15
urgical Procedure of Segmentectomy
t the hilum, isolation, division, and suture of the suitable seg-
ental bronchus, artery, and vein were required. Intraoperatively,
ymph nodes around the hilum and those obtained by mediastinal
issection or sampling were pathologically examined. Surgeons
ere allowed some latitude regarding the technique to detect and
ivide the intersegmental plane, including the use of electrocau-
ery, neodymium-yttrium-aluminum garnet laser, or segmental sta-
ling. Because a margin of at least 2 cm of healthy lung tissue was
equired, the resection line could be placed on the segment adja-
ent to the affected one or portions of a few adjacent segments or
ubsegments could be extirpated. After the resection, the surgeon
as obliged to corroborate that the tumor and required lymph
odes had been completely removed and proven to be negative for
nvolvement by frozen-section examination. It was specified that
hen the surgical margin was found to be imperfect or any lymph
ode was found to be diseased, lobectomy had to be performed
nstead.
Postoperatively, all complications including minor ones were
ecorded. Every patient was evaluated at 3-month intervals for the
rst 2 years, at 6-month intervals for the subsequent 3 years, and
early thereafter. Follow-up assessment included physical exami-
ation, hematologic and biochemical analysis including tumor
arkers, and chest roentgenograms. Local recurrence was defined
s recurrence at the primary site or in lymphatic drainage areas,
ither hilar or mediastinal within the operated thoracic cavity.
ber 2006
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TSistant metastasis was defined as intrapulmonary metastasis or
etastasis to other organs. Pulmonary function tests comprising
orced vital capacity (FVC) and forced expiratory volume in 1
econd (FEV1), were administered preoperatively and at 2 months
fter surgery.
tatistical Methods
isher’s exact test was used for intergroup comparison of categoric
ariables, and the Student t test was used for continuous data.
urvivals were estimated by the Kaplan-Meier method,16 and
ifferences in survival were determined by log-rank analysis.
ultivariate analysis with preoperative prognostic stratification
ariables was done using Cox proportional hazards regression
odel.17 Zero time was the date of pulmonary resection, and the
erminal event was death attributable to cancer, non-cancer, or
nknown causes for overall survival analysis. Operative mortality
efined as a 30-day postoperative death was included in the sur-
ival analyses. Disease-free survival was the interval from the date
f resection to proven detection of recurrence or metastases. Re-
urrent disease was defined as the discovery of any new lesion
onsidered to be recurrence of the original lung cancer. All patients
ere followed until death or study termination, unless lost to
ollow-up. Analyses of potential survival differences within sub-
roups and of potential prognostic factors were reported with
-sided P values.
esults
f the 567 patients preoperatively enrolled, 305 (53.8%)
ABLE 1. Base-line characteristics of the patients
haracteristic
Sublobar
resection group
(n  305)
Lobar
resection group
(n  262)
P
value
ender 0.8655
Male 167 (54.8%) 146 (55.7%)
Female 138 (45.2%) 116 (44.3%)
ge (years) 35-82 38-84 0.3312
mean: 63.2 mean: 64.0
istology 0.4772
AD 276 (90.5%) 229 (87.4%)
SQ 27 (8.9%) 30 (11.5%)
AS 2 (0.7%) 3 (1.1%)
ize 0.0564
Range 5-20 mm 8-20 mm
Mean 15.7 mm 16.2 mm
0-10 mm 36 21
11-20 mm 269 241
ocation 0.0191
Right upper lobe 101 (33.1%) 112 (42.7%)
Right lower lobe 54 (17.7%) 54 (20.6%)
Left upper lobe 106 (34.8%) 63 (24.0%)
Left lower lobe 44 (14.4%) 33 (12.6%)
D, Adenocarcinoma; SQ, Squamous cell carcinoma; AS, Adenosquamous
arcinoma. Fisher’s exact test was used to compare categoric variables,
nd student’s t test was used for continuous data.ere assigned to the sublobar resection group and 262 a
The Journal of Thoracic46.2%) were assigned to the lobar resection group. There
ere no significant differences in gender, age, or histologic
ype between the 2 groups (Table 1). The mean size of the
umor was a little smaller in the sublobar resection group,
lthough the observed difference was of borderline statisti-
al significance (P  .0564). However, location of the
umor was not well balanced (P  .0191). Patients with a
umor in the right upper lobe tended to be allocated to the
obar resection group, whereas those with a tumor in the left
pper lobe tended to be assigned to the sublobar resection
roup.
During the operation, the planned procedures were
hanged for various reasons (Figure 1). Forty-three of the
05 patients in the sublobar resection group underwent
obectomy. Among them, sufficient surgical margins were
ot obtained in 23 patients, N1 disease was diagnosed in 11
atients, and nodes were judged to be N2 positive intraop-
ratively in 9 patients. In addition, noncurative wedge re-
ection was carried out in 2 patients because pleural dis-
emination was found at the time of thoracotomy. Thus, 260
atients in the sublobar resection group underwent opera-
ion as planned, 230 patients underwent segmentectomy,
nd 30 patients underwent curative wedge resection. In
ontrast, thoracotomy without removal of the tumor was
erformed in 2 of the 262 patients enrolled in the lobar
esection group because of pleural dissemination.
The median follow-up of living patients in the sublobar
Figure 1. Treatment flow chart.nd lobar resection groups was 72 months (range, 29-155
and Cardiovascular Surgery ● Volume 132, Number 4 771
mt
g
e
w
n
i
i
p
c
r
w
m
5
c
p
m
a
t
a
c
m
o
o
d
a
q
S
F
s
s
a
s
v
t
a
r
r
p
d
a
b
b
a
t
P
B
F
C
s
s
T
C
C
P
P
R
F
General Thoracic Surgery Okada et al
7
G
TSonths) and 71 months (range, 22-158 months), respec-
ively. There were no significant differences between the 2
roups in curability, pathologic stage, incidence of postop-
rative complication, and recurrence (Table 2). It is note-
orthy that the rate of local recurrence did not differ sig-
ificantly between the 2 groups. Particularly, the recurrence
n the remaining part of the affected lobe that we had
ntentionally preserved with sublobar resection was our
rime concern. Among the 260 patients who underwent
urative sublobar resection, recurrence was detected in the
esidual part in 3 patients (1.2%). One patient who under-
ent segmentectomy of the left upper division for squa-
ous cell cancer showed recurrence in the surgical margin
months after surgery and is alive at 87 months after left
ompletion pneumonectomy. Another patient presented a
ulmonary metastasis just in the remaining portion at 49
onths after right S2 segmentectomy for adenocarcinoma
nd is alive at 16 months after completion lobectomy. The
hird patient with right S3 segmentectomy for papillary
denocarcinoma had occurrence of bronchioloalveolar car-
inoma at 40 months postoperatively and is surviving at 38
onths after completion lobectomy. All 3 patients are free
f disease at the time of this report. There was only 1
perative death in the sublobar resection group. The patient
ied of acute myocardial infarction 29 days after surgery,
lthough he had been discharged from the hospital after a
uick uneventful recovery.
urvival
igure 2 shows the disease-free and overall survivals of the
ublobar resection group and lobar resection group, demon-
ABLE 2. Postoperative findings of the patients
heracteristic
Sublobar
resection group
(n  305)
Lobar
resection group
(n  262)
P
value
urability 0.2577
Complete resection 303 (99.3%) 257 (98.1%)
Incomplete resection 2 (0.7%) 5 (1.9%)
athological stage 0.7819
IA 266 (87.2%) 217 (82.8%)
IB 7 (2.3%) 10 (3.8%)
IIA 10 (3.3%) 12 (4.6%)
IIB 2 (0.7%) 2 (0.8%)
IIIA 14 (4.6%) 15 (5.7%)
IIIB 6 (2.0%) 6 (2.3%)
ostoperative
complications
20 (6.6%) 19 (7.3%) 0.7429
ecurrence 43 (14.1%) 45 (17.2%) 0.3524
Distant metastasis 28 (9.2%) 27 (10.3%)
Local recurrence 15 (4.9%) 18 (6.9%)
isher’s exact test was used to compare categoric variables.trating no significant differences between them (P  .2778 s
72 The Journal of Thoracic and Cardiovascular Surgery ● Octond P  .106, respectively). Moreover, multivariate analy-
is using potential preoperative prognostic determinants re-
ealed that irrespective of gender, age, histologic type,
umor size, and tumor location, the disease-free interval
nd prognosis in the 2 groups were similar (Table 3; hazard
atio, 1.241, P  .3024 and hazard ratio, 1.363, P  .1537,
espectively). Next, we examined the surgical outcome in
atients who underwent curative resection for pT1N0M0
isease (Figure 3). Not surprisingly, the survival after cur-
tive wedge resection was good because the procedure had
een indicated for smaller tumors with possibly indolent
iologic behavior. Both the disease-free and overall surviv-
ls were comparable in patients in p-stage IA whether
reated with segmentectomy or lobectomy.
ulmonary Function
ecause lung function tests were not mandatory for this
igure 2. Disease-free survival (A) and overall survival (B).
urves correspond to patients who were initially enrolled for this
tudy (sublobar resection group, solid line; lobar resection group,
hort-dash line).tudy, information regarding the testing completed pre-
ber 2006
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G
TSperatively and postoperatively was available on 354
atients (62.4%). We analyzed the data according to the
rocedure actually executed. Preoperative functional val-
es were similar among the groups who underwent
edge resection (n  18), segmentectomy (n  168), and
obectomy (n  168), confirming that patients in the
ublobar resection group could have functionally toler-
ted a lobectomy (Table 4). In regard to both FVC and
EV1, the extent of resection seemed to correlate with the
eduction of lung function. Next, we directly compared
unctional changes between the 3 groups. Figure 4 clearly
emonstrates that the greater the resected amount of
issue, the more reduced the postoperative pulmonary
unction. Statistically significant differences in the ratio
f postoperative to preoperative FVC and FEV1 were
bserved among the 3 groups, although a marginal dif-
erence in FVC was seen between the segmentectomy
roup and the wedge resection group.
iscussion
t is of utmost importance to adequately resolve a contro-
ersial issue concerning the choice of resection for periph-
ral small early-stage NSCLCs, because the detection rate
f these lesions potentially amenable to effective treatment
ith lesser resection has dramatically increased in recent
ears. In 1995, the LCSG reported 1 randomized study
oncluding that lobectomy was the standard of care for
tage IA NSCLCs,1 which made a great impact on the
ollowing advance of lesser resection, although most recent
tudies comparing lesser resection with lobectomy for stage
ABLE 3. Proportional hazard model
ariables
Disease-free
survival Overall survival
Relative
risk
P
value
Relative
risk
P
value
ender
Male (vs Female) 1.761 0.0105 1.568 0.0531
ge
Older 1.012 0.2761 1.030 0.0168
istology
Non-AD (vs AD) 0.526 0.0909 1.149 0.6360
ize
Larger 1.098 0.0058 1.022 0.4994
ide
Left (vs Right) 1.307 0.2004 1.200 0.3976
obe
Upper (vs Lower) 1.483 0.1041 1.576 0.0667
nrolled group
Lobar (vs Sublobar) 1.241 0.3024 1.363 0.1537
D, Adenocarcinoma. Continuous data for age and size, and categories for
ender, histology, side, lobe, and enrolled group.A NSCLC demonstrated equivalent survival.8-13 Patel and t
The Journal of Thoracicolleagues4 raised several doubts about the analysis and
nterpretation of the results of the LCSG study. Their review
f the LCSG trial outcome suggested that patients with
esser resections may be at a higher risk of developing local
ecurrence, lower rate of perioperative lung morbidity, sim-
lar cancer-related mortality rate, and better preservation of
ung function compared with lobectomy for stage IA
SCLC. Table 5 shows a review of the literature regarding
he survivals after resection of stage IA (T1N0M0)
SCLC.1,8,9,12,18,19
The LCSG study showed a high incidence of local re-
urrence after sublobar resection, which we did not find in
ur series, although the methods of follow-up such as serial
T have been rapidly evolved year after year to identify
ocal recurrence. We are focusing on the high rate of wedge
esection in the sublobar resection group (32.8%), although
he LCSG study involved stage IA cancers including tumors
p to 3 cm in diameter. The predominance of wedge resec-
igure 3. Disease-free survival (A) and overall survival (B).
urves correspond to patients who underwent curative resection
or pT1N0M0 tumor (wedge resection, long-dash line; segmen-
ectomy, solid line; lobectomy, short-dash line).ion might affect the frequency of local recurrence. In our
and Cardiovascular Surgery ● Volume 132, Number 4 773
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G
TSeries, which included tumors up to 2 cm, the ratio of wedge
esection was 9.8%. The frequency of local recurrence after
ublobar resection could have been lower if the indication
ad been limited to tumors of 2 cm or smaller. In addition,
he reasons for the differences in the occurrence of local
ecurrence may be associated with our preference to favor
xtended segmentectomy, which can improve the treated
argin.8,9,12,13 The intraoperative lavage cytology of surgi-
al margins may be useful to check whether resection was
omplete.20 On the other hand, frequent application of
edge resection can result in less-extensive intraoperative
odal surveillance, leading to a potential understaging of
atients, in contrast with segmentectomy, which allows the
ssessment of nodal status. We are convinced that nodal
ssessment is obligatory for tumors larger than 2 cm.21 We,
nder strict policy, especially when planning a sublobar
esection, must resist the great temptation to perform an
asier operation such as wedge resection. Many proficient
urgeons have emphasized that segmentectomy must be
ssential and should not be forgotten by current-generation
horacic surgeons.22-26
The LCSG also reported that respiratory failure devel-
ped in 6 patients requiring postoperative ventilation for
ore than 24 hours in the lobectomy group, whereas no
atient in the sublobar resection group required ventilatory
ssistance.1 Longer ago, the LCSG found that the operative
ortality was 6.2% after pneumonectomy, 2.9% after lo-
ectomy, and 1.4% after sublobar resections in a universe of
220 resections for lung cancer.27 Preserving lung paren-
hyma can contribute to a lower occurrence of lung dys-
unction, complications, and operative deaths, which sug-
ests that perioperative morbidity and mortality rates would
e improved with a lesser resection.
An important positive result overlooked in the LCSG
rial is the advantage of sublobar resection concerning pul-
ABLE 4. Changes of lung function
rocedure
Preoperative
values
¡ Postoperative
values
edge resection (n  18)
FVC (L) 3.30 0.81 ¡ 3.10 0.69
FEV1.0 (L) 2.29 0.59 ¡ 2.21 0.84
FEV1.0/FVC (%) 70.2 12.1 ¡ 71.9 11.5
egmentectomy (n  168)
FVC (L) 3.16 0.84 ¡ 2.83 0.80
FEV1.0 (L) 2.32 0.64 ¡ 2.10 0.62
FEV1.0/FVC (%) 73.7 9.2 ¡ 74.8 10.0
obectomy (n  168)
FVC (L) 3.19 0.80 ¡ 2.68 0.77
FEV1.0 (L) 2.32 0.58 ¡ 1.93 0.58
FEV1.0/FVC (%) 73.2 8.3 ¡ 72.5 10.2
VC, forced volume capacity; FEV1.0, forced expiratory volume in 1 second.onary function.1 The FVC, FEV1, and maximum volun- r
74 The Journal of Thoracic and Cardiovascular Surgery ● Octoary ventilation were all significantly better in patients who
nderwent sublobar resection at 6 months after surgery. At
2 months the FEV1 was still significantly better. Recent
tudies have shown superior lung function after lesser re-
ection,10-12 and more recently Harada and colleagues28
emonstrated that the extent of removed lung parenchyma
y the segment affected that of postoperative functional loss
ven at 6 months after segmentectomy or lobectomy for
ung cancer. Our series revealed that sublobar resection
rovided better preservation of both FVC and FEV1 com-
ared with lobar resection at 2 months after surgery. These
ndings support that sublobar resection obviously offers a
unctional merit and constitute a more compelling reason to
onsider sublobar resection as identification of small can-
ers increases.
Possibly, not only a diseased margin but also intrapul-
onary metastases or involved intralobar nodes might de-
elop in the intentionally preserved lobe after sublobar
igure 4. FVC (A) and FEV1 (B) measured preoperatively and
ostoperatively (wedge resection, long-dash line; segmentec-
omy, solid line; lobectomy, short-dash line). Y-axis shows the
atio of the postoperative value to the preoperative one. Values
re presented as the mean  standard error. FVC, Forced vital
apacity; FEV1, forced expiratory volume in 1 second.esection. Under careful follow-up, in our series we identi-
ber 2006
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G
TSed 3 patients with local recurrence in the remaining part of
he diseased lobe after segmentectomy. At the time of this
eport all these patients are alive without disease after
ompletion lobectomy (n  2) or pneumonectomy (n  1).
n our study, as a result of careful selection of patients and
trict procedures, sublobar resection offered no survival
emerit over lobectomy. Despite the nonrandomized nature
f our study, our data force us to suggest that sublobar resec-
ion with sufficient margin and nodal assessment should
rovide appropriate treatment for stage I NSCLC of 2 cm or
maller in lieu of lobectomy in this era of increasing early
iscovery of small-sized lung cancer. We hereafter might
onsider the correlation between CT findings and bronchi-
loalveolar carcinoma component in the selection of pa-
ients for radical sublobar resection.29 At present, the time
s ripe for a large randomized trial, which would greatly
hange the standards of surgical treatment for lung cancer in
he near future.
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